Navigation Links
Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award

Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award.

A vaccine developed by University of Melbourne researchers that could eradicate a fatal form of brain disease will be delivered to Peru next week, and could soon be commercially available thanks to multi-million dollar funding.

The parasite Taenia solium causes 50 million tapeworm infections and 50,000 deaths from brain disease in the developing world each year. A major cash injection from the British Government and the Bill and Melinda Gates Foundation means that the vaccine will be registered and be produced on a commercial scale.

Although tapeworms can grow up to metres long and live in humans for years without health implications, their eggs can travel to the brain and cause paralysis and the often fatal condition of neurocysticercosis.

The disease results in cysts on the brain and spinal column, which is the most common cause of acquired epilepsy in the developing world and more than half the world's population living in countries where the parasite is endemic.

Professor Marshall Lightowlers at the Faculty of Veterinary Science has been striving towards the parasite's eradication for almost 30 years.

"I'm in a very lucky position that a lot of people dream and talk about, but virtually nobody reaches," said Professor Lightowlers.

"This disease has been identified as one that could be eradicated from the globe, so this is a very significant hurdle which means the end is well and truly in sight."

Five field trials were carried out in Peru, Cameroon, Mexico and Honduras between 2006 and 2008. All five trials achieved greater than 99% success.

The field trials have proved so successful that the team has been asked to provide 210,000 doses of the vaccine for a separate US$15.7m project funded by the Gates Foundation in Northern Peru, with the first of these doses arriving next week.

They will be used to treat 100,000 pigs in an area where the same number of humans are at risk of contracting the disease in the largest field trial of the vaccine to date.

Professor Lightowlers and his colleagues will travel to the infected regions where they have already trained local people to carry out the vaccinations; some from countries including Peru and Cameroon are now completing doctorates at the University.

University of Melbourne researchers have chosen to immunize pigs instead of humans with two intermuscular injections for piglets that prevent the animals from ever becoming infected but does not remove the disease from animals already infected.

"If we can prove that we can produce the vaccine commercially in a way that works in the field we will be looking at philanthropic groups for whom $100 million or $200 million isn't a lot of money to pay for the millions of doses needed to vaccinate pigs across the globe," he said.

In countries without proper sanitation, and where pigs and humans live in close quarters, there is a constant cycle of re-infection.

Pigs contract the tapeworm parasite from contact with human faeces, it is then passed on to humans who eat improperly cooked pig meat, and then more seriously, from human to human via exposure to tapeworm eggs in human faeces.

The vaccine will be developed and registered for commercial use by UK-based GALVmed, an organisation dedicated to the development of diagnostics, vaccines and medicines to tackle livestock diseases across the world.

GALVmed has secured US$28m from the UK Government's Department for International Development and the Gates Foundation for the development of vaccines, of which approximately US$5m is for the Taenia solium vaccine.

Professor Lightowlers says the vaccination could ultimately be delivered directly in humans, but developing it to that point would be a vastly more expensive process and one that would become irrelevant if the disease can be eradicated in pigs.


Contact: Nerissa Hannink
University of Melbourne

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Computers help chemists fight emerging infections
3. Study shines more light on benefit of vitamin D in fighting cancer
4. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
5. HIV Drug Might Fight Cancer
6. ADA Challenges Marylanders to Step Out to Fight Diabetes Epidemic
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Drug, Pacemaker Fight Irregular Heartbeat
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
Post Your Comments:
(Date:12/1/2015)... ... , ... Integrated Rental Services (“Integrated Rental”), a growing medical ... , With support from JII, Integrated Rental is poised for expansion while improving ... research labs and medical facilities across the United States. , General Manager Robert ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... we have seen vast improvements in scientific research and discoveries, leading us to ... increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: